Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

• Status: Recruiting
• Trial end date: 2021-03-01
• Target enrollment: 0
• Participant gender: All

Summary

COVID-19's high mortality may be driven by hyperinflammation. Interleukin-6 (IL-6) axis therapies may reduce COVID-19 mortality. Retrospective analyses of tocilizumab in severe to critical COVID-19 patients have demonstrated survival advantage and lower likelihood of requiring invasive ventilation following tocilizumab administration. The majority of patients have rapid resolution (i.e., within 24-72 hours following administration) of both clinical and biochemical signs (fever and CRP, respectively) of hyperinflammation with only a single tocilizumab dose.

The investigators hypothesized that a dose of tocilizumab significantly lower than the EMA- and FDA-labeled dose (8mg/kg) as well as the emerging standard of care dose (400mg) may be effective in patients with COVID-19 pneumonitis and hyperinflammation. Advantages to the lower dose of tocilizumab may include lower likelihood of secondary bacterial infections as well as extension of this drug's limited supply. The investigators conducted an adaptive single-arm phase 2 trial (NCT04331795) evaluating clinical and biochemical response to low-dose tocilizumab in patients with COVID-19 pneumonitis and hyperinflammation.

This multi-center, prospective, randomized controlled phase 2 trial -- designed as two sub-studies to allow for the possible emergence of data demonstrating the clinical efficacy of tocilizumab 8mg/kg or 400mg -- formally tests the clinical efficacy of low-dose tocilizumab in COVID-19 pneumonia.

Sub-Study A Primary Objective A: To establish whether low-dose tocilizumab reduces the time to clinical recovery in patients with COVID-19 pneumonitis and hyperinflammation, when compared to a tocilizumab-free standard of care.

Hypothesis A: The investigators hypothesize that low-dose tocilizumab, when compared to a tocilizumab-free standard of care, decreases the time to recovery in hospitalized, non-invasively ventilated patients with COVID-19 pneumonitis and hyperinflammation by three days or more.

Sub-Study B Primary Objective B: To establish whether low-dose tocilizumab is near-equivalent to high-dose tocilizumab (400mg or 8 mg/kg) in reducing the time to clinical recovery in patients with COVID-19 pneumonitis and hyperinflammation.

Hypothesis B: The investigators hypothesize that low-dose tocilizumab is near-equivalent to high-dose tocilizumab in reducing the time to clinical recovery in hospitalized, non-invasively ventilated patients with COVID-19 pneumonitis and hyperinflammation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago

Criteria

Inclusion Criteria:

• Adults ≥ 18 years of age

• Approval from the patient's primary inpatient service

• Hospitalized

• Fever, documented in electronic medical record and defined as: T ≥ 38 degrees C by any conventional clinical method (forehead, tympanic, oral, axillary, rectal)

• Positive test for active SARS-CoV-2 infection

• Radiographic evidence of infiltrates on chest radiograph (CXR) or computed tomography (CT)

• Ability to provide written informed consent on the part of the subject or, in the absence of decisional capacity of the subject, an appropriate surrogate (e.g. a legally authorized representative).

Exclusion Criteria:

• Concurrent use of invasive mechanical ventilation

• Concurrent use of vasopressor or inotropic medications

• Previous receipt of tocilizumab or another anti-IL6R or IL-6 inhibitor in the year prior.

• Known history of hypersensitivity to tocilizumab.

• Diagnosis of end-stage liver disease or listed for liver transplant.

• Elevation of AST or ALT in excess of 10 times the upper limit of normal.

• Neutropenia (Absolute neutrophil count < 500/uL).

• Thrombocytopenia (Platelets < 50,000/uL).

• On active therapy with a Bruton's tyrosine kinase-targeted agent, which include the following:

• Acalabrutinib

• Ibrutinib

• Zanubrutinib

• On active therapy with a JAK2-targeted agent, which include the following:

• Tofacitinib

• Baricitinib

• Upadacitinib

• Ruxolitinib

• Any of the following biologic immunosuppressive agent (and any biosimilar versions thereof) administered in the past 6 months or less::

• Abatacept

• Adalimumab

• Alemtuzumab

• Atezolizumab

• Belimumab

• Blinatumomab

• Brentuximab

• Certolizumab

• Daratumumab

• Durvalumab

• Eculizumab

• Elotuzumab

• Etanercept

• Gemtuzumab

• Golimumab

• Ibritumomab

• Infliximab

• Inotuzumab

• Ipilimumab

• Ixekizumab

• Moxetumomab

• Nivolumab

• Obinutuzumab

• Ocrelizumab

• Ofatumumab

• Pembrolizumab

• Polatuzumab

• Rituximab

• Rituximab

• Sarilumab

• Secukinumab

• Tocilizumab

• Tositumumab

• Tremelimumab

• Urelumab

• Ustekinumab

• History of bone marrow transplantation (including chimeric antigen receptor T-cell) or solid organ transplant

• Known history of Hepatitis B or Hepatitis C (patients who have completed curative-intent anti-HCV treatments are not excluded from trial)

• Positive result on hepatitis B or C screening

• Known history of mycobacterium tuberculosis infection at risk for reactivation

• Known history of gastrointestinal perforation

• Active diverticulitis

• Multi-organ failure as determined by primary treating physicians

• Any other documented serious, active infection besides COVID-19 - including but not limited to: lobar pneumonia consistent with bacterial infection, bacteremia, culture-negative endocarditis, or current mycobacterial infection - at the discretion of primary treating physicians

• Pregnant patients or nursing mothers

• Patients who are unable to discontinue scheduled antipyretic medications, either as monotherapy (e.g., acetaminophen or ibuprofen [aspirin is acceptable]) or as part of combination therapy (e.g., hydrocodone/acetaminophen, aspirin/acetaminophen/caffeine [Excedrin®])

• CRP < 40 mg/L